SEC For	rm 4 FORM	Л		sד ר	ΔΤΕ	s s	FCU	RITIF	ς ανη	F	ХСНАМ		оммі	SSION						
	ONTE	JNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549														VAL				
Section 16. Form 4 or Form 5 obligations may continue. See						NT OF CHANGES IN BENEFICIAL OWNERSHIP														
1. Name and Address of Reporting Person*						or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of F Kozar Life Sciences Inc [KZP] (Check all applicab										g Pers	on(s) to Iss	uer		
Garner Elizabeth						<u>Rezar Life Sciences, inc.</u> [KZK]									X Director 10% Owner Officer (give title Other (specify below) below)					
(Last) (First) (Middle)						07/24/2023														
C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300					4.	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Include:									,					
(Street) SOUTH SAN															Form filed by More than One Reporting Person					
FRANCISCO CA 94080				R	Rule 10b5-1(c) Transaction Indication															
(City) (State) (Zip)							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
			ble I - Noi						·	Dis	1	,								
1. Title of Security (Instr. 3)			Date	2. Transaction Date Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquire Disposed Of (D) (Inst 5)			5. Amoun Securities Beneficia Owned For Reported	ially (D) Following (I) (		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D) Price		Transacti (Instr. 3 a	tion(s)			(11501-4)		
			Table II -								osed of, o onvertib			Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	onversion Date Execution Exercise (Month/Day/Year) if any ice of rrivative		Date, Trai Cod		action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)		te	7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(A) (D)		ole	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)					
Stock Option (Right to Buy)	\$3.03	07/24/2023			D			17,793	(1)		12/17/2029	Common Stock	17,793	(2)	0		D			
Stock Option (Right to Buy)	\$2.28	07/24/2023			A		17,793		(1)		12/17/2029	Common Stock	17,793	(2)	17,79	3	D			
Stock Option (Right to Buy)	\$5.6	07/24/2023			D			8,896	(1)		06/23/2030	Common Stock	8,896	(2)	0		D			
Stock Option (Right to Buy)	\$2.28	07/24/2023			A		8,896		(1)		06/23/2030	Common Stock	8,896	(2)	8,896	5	D			
Stock Option (Right to Buy)	\$5.59	07/24/2023			D			26,000	(1)		06/27/2031	Common Stock	26,000	(2)	0		D			
Stock Option (Right to Buy)	\$2.28	07/24/2023			A		26,000		(1)		06/27/2031	Common Stock	26,000	(2)	26,00	0	D			
Stock Option (Right to Buy)	\$4.8	07/24/2023			D			26,000	(1)		06/15/2032	Common Stock	26,000	(2)	0		D			
Stock Option (Right to Buy)	\$2.28	07/24/2023			Α		26,000		(1)		06/15/2032	Common Stock	26,000	(2)	26,00	0	D			

Explanation of Responses:

1. Fully vested and exercisable.

2. On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to \$2.28 per share. All of the other terms of the option remain unchanged.

Remarks:

## <u>/s/ Marc Belsky, Attorney-in-</u> Fact

07/26/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.